Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM:

Multiple Sclerosis Journal – Experimental, Translational and Clinical

Minhua Yang¹  Jing L Marantz²  Douglas L Arnold²  Amit Bar-Or³  Gavin Giovannoni⁴  Ralf Gold⁵  Ludwig Kappos⁶ 

[1] Biogen, USA;Montreal Neurological Institute, McGill University, Canada;NeuroRx Research, Montreal, Canada;Queen Mary University London, UK;St Josef Hospital, Ruhr University, Germany;University Hospital, Basel Neurology, Switzerland

关键词: Delayed-release dimethyl fumarate;    multiple sclerosis;    disability evaluation;    Multiple Sclerosis Functional Composite;    disease progression;    neuropsychological tests;   

DOI  :  10.1177/2055217316634111

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

The effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the Multiple Sclerosis Functional Composite (MSFC) was assessed using integrated Phase 3 DEFINE and CONFIRM data. Patients treated with DMF (n = 769) demonstrated significant superiority on the MSFC, and each component, compared with placebo (n = 771) over two years: mean change for DMF vs placebo was 0.054 vs −0.053 on MSFC; −0.088 vs −0.286 on Timed 25-Foot Walk, 0.047 vs 0.003 on 9-Hole Peg Test and 0.178 vs 0.123 on Paced Auditory Serial Addition Test. DMF was an efficacious treatment for patients with MS.

【 授权许可】

CC BY-NC